Gastrointestinal stromal tumour (GIST) is the most common human sarcoma and is primarily defined by activating mutations in the KIT or PDGFRA receptor tyrosine kinases 1,2 . KIT is highly expressed in interstitial cells of Cajal (ICCs)-the presumed cell of origin for GIST-as well as in haematopoietic stem cells, melanocytes, mast cells and germ cells 2,3 . Yet, families harbouring germline activating KIT mutations and mice with knock-in Kit mutations almost exclusively develop ICC hyperplasia and GIST 4-7 , suggesting that the cellular context is important for KIT to mediate oncogenesis. Here we show that the ETS family member ETV1 is highly expressed in the subtypes of ICCs sensitive to oncogenic KIT mediated transformation 8 , and is required for their development. In addition, ETV1 is universally highly expressed in GISTs and is required for growth of imatinib-sensitive and resistant GIST cell lines. Transcriptome profiling and global analyses of ETV1-binding sites suggest that ETV1 is a master regulator of an ICC-GIST-specific transcription network mainly through enhancer binding. The ETV1 transcriptional program is further regulated by activated KIT, which prolongs ETV1 protein stability and cooperates with ETV1 to promote tumorigenesis. We propose that GIST arises from ICCs with high levels of endogenous ETV1 expression that, when coupled with an activating KIT mutation, drives an oncogenic ETS transcriptional program. This differs from other ETS-dependent tumours such as prostate cancer, melanoma and Ewing sarcoma where genomic translocation or amplification drives aberrant ETS expression 9-11 . It also represents a novel mechanism of oncogenic transcription factor activation.
Gastrointestinal stromal tumour (GIST) is the most common human sarcoma and is primarily defined by activating mutations in the KIT or PDGFRA receptor tyrosine kinases 1, 2 . KIT is highly expressed in interstitial cells of Cajal (ICCs)-the presumed cell of origin for GIST-as well as in haematopoietic stem cells, melanocytes, mast cells and germ cells 2, 3 . Yet, families harbouring germline activating KIT mutations and mice with knock-in Kit mutations almost exclusively develop ICC hyperplasia and GIST [4] [5] [6] [7] , suggesting that the cellular context is important for KIT to mediate oncogenesis. Here we show that the ETS family member ETV1 is highly expressed in the subtypes of ICCs sensitive to oncogenic KIT mediated transformation 8 , and is required for their development. In addition, ETV1 is universally highly expressed in GISTs and is required for growth of imatinib-sensitive and resistant GIST cell lines. Transcriptome profiling and global analyses of ETV1-binding sites suggest that ETV1 is a master regulator of an ICC-GIST-specific transcription network mainly through enhancer binding. The ETV1 transcriptional program is further regulated by activated KIT, which prolongs ETV1 protein stability and cooperates with ETV1 to promote tumorigenesis. We propose that GIST arises from ICCs with high levels of endogenous ETV1 expression that, when coupled with an activating KIT mutation, drives an oncogenic ETS transcriptional program. This differs from other ETS-dependent tumours such as prostate cancer, melanoma and Ewing sarcoma where genomic translocation or amplification drives aberrant ETS expression [9] [10] [11] . It also represents a novel mechanism of oncogenic transcription factor activation.
Reasoning that transcription factors are likely to play critical roles in defining the cellular context, we used three expression data sets 12, 13 to search for GIST-specific genes that might provide new molecular insights. We identified an 11-gene signature exclusively associated with GIST in all three data sets that included the ETS family transcription factor ETV1 ( Fig. 1a and Supplementary Table 1 ). Examination of individual tumour samples revealed that ETV1 is highly expressed in all GISTs and at significantly higher levels than any other tumour type ( Fig. 1b and Supplementary Fig. 1 ). ETV1 was of immediate interest because ETS family transcription factors are well-established oncogenes in Ewing sarcoma, melanoma and prostate cancer [9] [10] [11] .
Next, we assessed messenger RNA (mRNA) and protein levels of ETV1 in GIST and other sarcomas in clinical samples, GIST cell lines (imatinib-resistant GIST48 and imatinib-sensitive GIST882), the U2OS osteosarcoma cell line and the LNCaP prostate cancer cell line known to overexpress ETV1 owing to translocation 14 (Fig. 1c, d) . ETV1 mRNA and protein were highly and exclusively expressed in all GIST tumour samples and GIST cell lines, and in LNCaP cells. As expected, KIT mRNA and protein were highly expressed in all GIST tumours and GIST cell lines, but not in other sarcomas or non-GIST cell lines, and phospho-KIT was only seen in GIST samples with activating KIT mutations. Four additional GIST samples amenable to immunohistochemical analysis all showed strong nuclear ETV1 staining whereas a leiomyosarcoma control sample did not (Supplementary Fig. 2 ). These data show that ETV1 is universally highly expressed in all GISTs both at transcript and protein levels.
To explore the requirement of ETV1 in GIST pathogenesis, we performed RNAi experiments using two ETV1-specific hairpins validated for both protein and mRNA suppression ( Supplementary Fig. 3a ). Infection with either hairpin resulted in growth inhibition of both GIST cell lines, but did not affect the growth of U2OS cells. Consistent with the level of ETV1 knockdown, ETV1sh2 was more growth suppressive than ETV1sh1 in both GIST cell lines ( Fig. 1e ). Cell cycle analysis showed that ETV1 knockdown resulted in both decreased cell cycle progression and increased apoptosis ( Supplementary Fig. 3b ). ETV1 knockdown also impaired the tumorigenicity of GIST882 cells in SCID mouse xenografts, and those tumours that did grow had escaped ETV1 suppression ( Fig. 1f ). Collectively, these observations indicate that ETV1 is required for GIST growth and survival.
Next, we addressed the mode of high ETV1 expression in GIST. Fluorescence in situ hybridization on four GIST samples and two GIST cell lines showed no evidence of amplification or 'breakaway' between the 39 and 59 ends of ETV1 locus. Quantitative reverse transcription PCR showed no evidence of differential exon expression, which is expected with ETV1 translocation ( Supplementary Fig. 4 ). Furthermore, no focal ETV1 amplification was found in 40 GIST tumours and six GIST cell lines in a recent high-density single nucleotide polymorphism array study 15 . The fact that high levels of ETV1 expression are consistently observed in the absence of obvious genomic alterations raises the possibility that the ICCs that give rise to GIST may endogenously express ETV1.
The musculature of the gastrointestinal tract is organized into two principal layers-the inner circular muscle layer beneath the mucosa and the outer longitudinal muscle layer 16 . In the large intestine, myenteric ICCs (ICC-MY) form a network between the circular muscle and longitudinal muscle layers surrounding the neuronal myenteric plexus, intramuscular ICCs (ICC-IM) are singly dispersed in the circular muscle, and submucosal ICCs (ICC-SMP) form network surrounding the submucosal plexus ( Fig. 2a ). In the small intestine, ICC-IMs and ICC-SMPs are absent and ICC-DMPs form a network around the deep muscular plexus in the circular muscle close to the mucosa (Supplementary Fig. 5a ). All four ICC subtypes are identified by positive membrane expression of Kit 16 ( Fig. 2b and Supplementary Fig. 5b ). In the large intestine, ICC-MYs and ICC-IMs but not ICC-SMPs stain with nuclear Etv1 (Fig. 2b ). In the small intestine, ICC-MYs but not ICC-DMPs stain with nuclear Etv1 ( Supplementary Fig. 5b ). This finding is further supported by our analysis of a published ICC expression data set from mouse small intestine 17 showing that Etv1 is only highly expressed in ICC-MYs ( Supplementary Fig. 5c ). Notably, in the Kit D558 mutant mice only ICC-MY and ICC-IM develop hyperplasia whereas ICC-SMP and ICC-DMP do not 8 . These data suggest that ETV1 is a lineage-specific transcription factor for the ICCs that give rise to GIST.
We therefore asked if Etv1 is required for the normal development of ICCs by examining the gastrointestinal tracts of Etv1 2/2 mice 18 . Cross-section and reconstructed whole-mount images from Etv1 2/2 mice showed significant loss of Kit-positive ICC-IMs and ICC-MYs in the large intestine ( Fig. 2c, d , Supplementary Fig. 9 and Supplementary Movies 1 and 2), small intestine, stomach and caecum (Supplementary Figs 6-9 and Supplementary Movies 3-8). In contrast, ICC-DMPs and ICC-SMPs in the small and large intestine, respectively, were preserved, consistent with absent Etv1 expression in these ICC subtypes. These results were confirmed with a second ICC marker Ano1 (ref. 19) ( Supplementary Fig. 10 ). Immunostaining with the neuronal marker Pgp9.5 confirmed the integrity of the myenteric plexus in Etv1 2/2 mice ( Fig. 2c and Supplementary Figs 6-8 and 11). Collectively, these data indicate that Etv1 is selectively required for development of ICC-MY and ICC-IM and, by implication, a lineage-specific survival factor for the ICC-GIST lineage.
To identify ETV1 target genes in GIST, we analysed the effect of short hairpin RNA (shRNA)-mediated ETV1 suppression on the transcriptomes of GIST48 and GIST882 cells. The overlap of genes perturbed by both ETV1-specific hairpins and across both cell lines was highly statistically significant, suggesting that ETV1 regulates a core set of genes in GIST ( Supplementary Fig. 12 ). To minimize cell-linespecific and off-target effects, we generated a ranked gene list based on the average change in gene expression induced by the two ETV1specific hairpins in both GIST cell lines ( Fig. 3a, b ). We independently confirmed downregulation of five of these genes using real-time PCR ( Supplementary Fig. 13 ). Among the 48 genes suppressed more than 1.7-fold by ETV1 knockdown, 32 were expressed at higher levels in human GIST samples relative to other tumour types in the ExpO expression data set ( Fig. 3b ). We performed gene set enrichment analysis 20 of the 'shETV1' ranked list using more than 3,000 gene sets in the Molecular Signature Database and five custom gene sets defined by GIST-signature genes from the Segal, Nielsen and ExpO data sets and by ICC-MY-and ICC-DMP-signature genes (Supplementary Table 1 ). All three GIST sets and the ICC-MY set were among the most negatively enriched gene sets whereas the ICC-DMP set was not ( Fig. 3c , Supplementary Fig. 14 and Supplementary Table 2 ). These data suggest that ETV1 is a master regulator of a transcriptional program conserved in ICC-IM/MYs and GISTs. 
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To define the direct transcriptional targets of ETV1 in GIST, we performed genome-wide analyses of ETV1-binding sites using chromatin immunoprecipitation and deep sequencing (ChIP-Seq) in GIST48 cells. We identified 14,741 ETV1-binding sites (ETV1 peaks), which are enriched in promoter regions (Fig. 3d ). Motif analysis of the peaks identified the ETS core consensus motif, GGAA, in approximately 90% of peaks ( Fig. 3f ). Integrative analyses of the ETV1 ChIP-Seq data with the transcriptomes from shRNA-mediated ETV1 suppression in GIST cells showed that 38 of the top 48 shETV1 downregulated genes contain ETV1 peaks (Fig. 3b, e and Supplementary Fig. 15 ). Analysis of genes with 1.4-fold change by shETV1 knockdown revealed that both shETV1 upregulated and shETV1 downregulated genes are enriched for ETV1 peaks. Furthermore, enhancer binding, in particular enhancer and promoter binding, is highly predicative of transcriptional activation by ETV1 ( Fig. 3h ). Because enhancers are in general cell-lineage specific 21, 22 , our data suggest that these ICC-GIST-lineage-specific genes are likely directly regulated by ETV1 binding to their enhancer regulatory elements.
The dual requirement of KIT and ETV1 in normal ICC development and GIST survival raises the possibility that KIT and ETV1 cooperate in GIST oncogenesis. Inhibition of KIT signalling by imatinib in imatinibsensitive GIST882 cells resulted in rapid loss of ETV1 protein, without significant effect on ETV1 mRNA levels (Fig. 4a, b and Supplementary  Fig. 16 ). Similar results were observed with the MEK inhibitor PD325901. This loss of ETV1 protein was faster than the natural degradation rate, as revealed by cyclohexamide experiments to inhibit protein synthesis, and was rescued from proteosomal degradation by MG132 (Fig. 4b) . Therefore, KIT-MEK signalling stabilizes ETV1 protein. Consistent with this KIT-MEK-ETV1 signalling pathway model, the overlap between genes transcriptionally altered by imatinib treatment (KIT-regulated) and by ETV1 knockdown in GIST882 cells is highly significant (Fig. 4c ). Furthermore, these ETV1 transcriptional targets preferentially contain ETV1 enhancer peaks (Fig. 4d ), which indicates that KIT signalling influences the ETV1 transcriptional output of the tissue and lineage-specific genes in GIST.
Having established a signalling pathway from KIT to ETV1, we explored their potential cooperativity in tumorigenesis by expressing ETV1, wild-type KIT, KIT harbouring a common GIST mutation (KITD560) and control vectors in combination in NIH3T3 cells. KIT-dependent stabilization of ETV1 protein was recapitulated in this system (Fig. 4e ). In anchorage-independent colony formation assays, ETV1 significantly increased the number and size of colonies in KITD560 expressing cells but was insufficient to confer anchorageindependent growth on its own ( Supplementary Fig. 17 ). Furthermore, KITD560 and ETV1 strongly cooperated in conferring tumorigenic growth in SCID mice ( Fig. 4f, g) .
Taken together, these findings establish an oncogenic role for ETV1 in GIST that differs from classical models of ETS-driven malignancies where structural alterations (for example, TMPRSS2-ETV1 translocation in prostate cancer, ETV1 amplification in melanoma) lead to aberrant expression and promote tumorigenesis 9, 11 . Rather, ETV1 expression in GIST is inherited from ICC-MY/IM cells, where ETV1 is also a survival factor. We further established that KIT activity, through MEK, stabilizes ETV1, providing a mechanism for KIT-ETV1 cooperativity (Fig. 4h) . These observations provide an explanation for why patients and mice with germline-activating KIT mutations develop neoplasia in only the ICC-MY/IM lineage. Although the mechanism of ETV1-mediated oncogenesis in GIST differs from other ETS-driven cancers, we anticipate that the ETV1-dependent transcriptional program defined here may serve as a valuable resource for further understanding of other ETV1-and other ETS-driven transcriptional programs in various cellular contexts such as prostate cancer.
The fact that ETV1 is universally highly expressed in all GISTs makes it immediately useful as a candidate diagnostic biomarker, because the current standard of KIT immunoreactivity is negative in about 5% of all GISTs 23 . Although transcription factors have classically been considered 'undruggable', reports of successful inhibition of the NOTCH transcription factor complex and androgen receptor activity by blocking coactivator binding have challenged this model 24, 25 . Owing to established requirements of ETV1 in subsets of prostate cancer and CTSL1  ETV1  TIMP3  PTPRE  FABP5  SYTL2  TMEM163  DUSP6  GDF10  GPR20  SOCS1  C1orf69  ISLR  SHANK2  MEST   LGI2  ALDH1A3  STIM2  GPBAR1  MLLT11  TBX2  FABP4  PIK3CG  SIPA1L2  CST1  C3orf54  ACTR2  GEM  NPR3  F2RL2   SMTN   SERBP1   MYH13  C1QTNF7  TSPAN5  XCL1  PNPO  EML1  KLHL23  WWC1  DISP1  EDN3  IGDCC3  RPS7  KCTD10 
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melanoma, efforts to find ETV1 inhibitors are underway and may yield novel therapeutic agents for imatinib-resistant GIST.
METHODS SUMMARY
All mined data sets were downloaded from Gene Expression Omnibus (GSE2109, GSE7809, GSE2719, GSE3443, GSE8167, GSE17743) and were analysed by Oncomine or by using Genespring 10. GIST-signature genes from three data sets containing both GIST and non-GIST malignancies met the following two criteria:
(1) q , 0.05 and (2) a Z-score expression difference more than 1.5 between GIST and non-GIST tumours. Expression profiling of GIST cell lines with different shRNA conditions was performed in duplicate on Illumina HumanHT-12 array.
Gene set enrichment analysis was performed using MSigDB C2, MSigDB C4 and the GIST and ICC signature gene sets. For ChIP-Seq, sheared chromatin enriched by ETV1 IP was sequenced on Solexa Genome Analyser, aligned using ELAND software. Peaks were identified by Model-based Analysis of ChIP-Seq (MACS) with input DNA as control using a false discovery rate of less than 1%. Materials. GIST48 and GIST882 cells were established in the Fletcher laboratory 26 . All other cells were obtained from the American Type Culture Collection. Etv1 2/2 mice, with targeted deletion of the ETS domain, were obtained from the Jessell laboratory (Columbia) and CB17-SCID mice were from Taconic. Antibody sources were ETV1, ANO1, PGP9.5 (Abcam), KIT for western blotting, P-Tyr703-KIT (Cell Signaling), P-Tyr204-ERK, GAPDH (Santa Cruz) and anti-mouse Kit for immunofluorescence (clone ACK2, E-Biosciences). b, Immunoblots of GIST882 cells treated for 2 h with imatinib or PD325901 in combination with cyclohexamide (10 mg ml 21 ) or MG132 (10 mM). c, Venn diagram of genes downregulated by 1.4-fold by shETV1 and by imatinib in GIST882 cells. P value: Fisher's exact test based on number of expressed genes. d, Percentage of all genes, imatinib-downregulated genes, shETV1downregulated genes and overlapping genes with ETV1 enhancer peaks. e, Immunoblot of NIH3T3 cells expressing ETV1 and either KIT WT or KITD560 2 h after treatment with PD325901, imatinib or MG132. f, Growth of xenografts of engineered NIH3T3 cells stably expressing the indicated genes (n 5 12, mean 6 s.e.m.). g, Photograph of four representative explanted xenografts at 4 weeks after implanting. Scale bar, 1 cm. h, Model of the role of ETV1 in ICC maintenance and GIST oncogenesis. Normal level of KIT activation by KIT ligand (red triangle) stabilizes ETV1 transcription factor through the MAPK pathway, and results in physiological ETV1 transcriptional output critical for ICC development (middle). In the absence of ETV1, there is decreased ICC development, which phenocopies genetic loss of KIT signalling (left). Activating mutation of KIT (for example, KITD560) leads to constitutive activation of the KIT-MAPK signalling pathway, increased ETV1 stability and augmented ETV1 transcriptional output that promotes tumorigenesis (right).
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KITD560, 1 3 10 6 cells were implanted as above and tumour sizes were measured starting 2 weeks after xenografting. Anchorage independent growth. Transduced NIH-3T3 cells were suspended in soft agar with 20% calf-serum at 5,000 cells per well in a six-well plate in triplicate. After 3 weeks, each well was stained with 0.5% crystal violet, imaged and counted using GelCount (Oxford Optronix).
Immunofluorescence. For ETV1 immunofluorescence of paraffin sections of tumour samples, heat-mediated antigen retrieval was performed followed by staining with ETV1 antibody at 2.5 mg ml 21 and Alexa-594 labelled anti-rabbit secondary antibody. For immunofluorescence of cryostat sections of the mouse gastrointestinal tract, mouse stomach, small intestine, caecum and large intestine were dissected and fixed in 4% paraformaldehyde for 2 h followed by an overnight incubation in 30% sucrose. They were then embedded in OCT, flash frozen and cut into 5-mm sections using a cryostat. Etv1 2/2 and Etv1 1/1 littermate controls were embedded onto the same block to ensure identical processing. Tissue sections were blocked overnight using 5% goat serum, incubated with primary antibodies at 4 uC overnight, and secondary antibody for 2 h at room temperature. Slides were mounted using Prolong Gold (Invitrogen) and images were taken on a Nikon Eclipse TE2000-E microscope using a Photometric Coolsnap HQ camera. Images were taken with 320 (numerical aperture 0.75) or 360 (numerical aperture 1.4) objectives. Monochrome images taken with DAPI, FITC and Texas Red filter sets were pseudo-coloured blue, green and red, respectively, and merged using ImageJ (http://rsbweb.nih.gov/ij/). The exposure, threshold and maximum were identical between Etv1 2/2 and Etv1 1/1 images.
For whole-mount staining, mouse gastrointestinal tissue was fixed in ice-cold acetone for more than 1 h. It was then rehydrated in PBS, stretched and the mucosa of these gastrointestinal tissues was blunt dissected away. Samples were then blocked in 5% goat serum, incubated with ACK2 rat-anti-KIT antibody or PGP9.5 antibody, followed by secondary antibody. Images were taken with 320 (numerical aperture 0.75) or 360 (numerical aperture 1.4) objectives with a Z-step of 1 mm through the muscle layer. The Z-stack of images was deconvoluted using Autoquant X2 software (Media Cybernetics). Movies were generated from deconvolued stacks using ImageJ software.
To quantify ICC subsets, immunofluorescence images from at least four fields each from two Etv1 1/1 and Etv1 2/2 mice (at least eight fields in total) of the stomach, small intestine, caecum and large intestine were examined. A percentage of ICCs were obtained by dividing the total number of KIT-positive immunostaining cells by the number of DAPI-positive nuclei. The results are shown as the percentage of residual KIT-positive immunostaining in Etv1 2/2 mice compared with Etv1 1/1 controls. Expression profiling. For profiling of ETV1 knockdown, GIST48 and GIST882 cells plated in 12-well plates were infected in triplicates with shScr, and ETV1sh1 and ETV1sh2 viruses at MOI 5 5. Four days after infection, RNAs were isolated from duplicate samples and protein lysates were obtained from the third for confirmatory ETV1 western blot. The duplicate samples were expression profiled using an Illumina HumanHT-12 array. Raw data was imported into Genespring 10, quartile normalized and log 2 transformed. The log transformed expression value of each probe was averaged across duplicates. For each probe, the average change by ETV1 knockdown is calculated as ((ETV1sh1 GIST48 2ShScr GIST48 ) 1 (ETV1sh2 GIST48 2ShScr GIST48 ) 1 (ETV1sh1 GIST882 2 ShScr GIST882 ) 1(ETV1sh2 GIST882 2 ShScr GIST882 ))/4. We next generated a ranked list of genes based on the averaged log 2 transformed fold change. The top 48 genes showed an average decrease of greater than 1.7-fold with ETV1 knockdown (Fig. 2) . We defined a 'shETV1 DN' gene set as the 410 genes with an average decrease greater than 1.4-fold and a 'shETV1 UP' gene set as the 380 genes with an average increase of greater than 1.4-fold.
For profiling of imatinib treatment, GIST882 cells were treated with vehicle or 1 mM imatinib for 8 h in triplicate and profiled as above. Gene set enrichment analysis. Given a ranked list of genes, GSEA determines whether predefined sets of genes (for example, genes within a Gene Ontology category) are disproportionally overrepresented in the top or the bottom of the list instead of randomly across the list 20 . To assess the phenotypic association with ETV1 knockdown, we used the ranked list of genes generated above from the most upregulated by ETV1 knockdown to most downregulated by ETV1 knockdown.
For genes with multiple probes by the Illumina HumanHT-12 array, the median signal was used. We used gene sets from the Molecular Signatures Database C2 version 2.5 with 1,892 curated gene sets of chemical and genetic perturbations and canonical pathways and C5 version 2.5 with 1,454 Gene Ontology gene sets. In addition, we added five custom gene sets including the three GIST signature gene sets EXPO_GIST_SIG, NIELSEN_GIST_SIG and SEGAL_GIST_SIG and two ICC signature gene sets ICC_MY_SIG and ICC_DMP_SIG, defined above. ChIP-Seq. ChIP-Seq was performed as previously described 31 . Briefly, 10 8 GIST48 cells were crosslinked for 15 min in 1% paraformaldehyde, washed and lysed. Chromatin was sheared using Bioruptor (Diagenode) to fragments of approximately 150 base pairs and was incubated with anti-rabbit IgG Dynabeads (Invitrogen) preconjugated with anti-ETV1 antibody, washed and eluted. The eluted chromatin was reverse-cross-linked, and DNA was column purified. The purified ChIP DNA was blunt-ended, ligated to Solexa adaptors, amplified with 18 cycles of PCR and sequenced on a Solexa Genome Analyser. We performed independent quantitative PCR validation of separate ChIP samples using the following primers: DUSP6 promoter: F: GCCCGCTGTTGCAGCTTGTT, R: GCCGGCTGGAAC AGGTTGTG GPR20 enhancer: F: CCCTCCCAGGCTCTCCCCAC, R: TCCGGGCCTGCTCT CTGTCC GAPDH promoter: F: TCCCAAAGTCCTCCTGTTTCA, R: CAGCAGGACAC TAGGGAGTCAA.
All reads (approximately 150 base pairs) were aligned to the human genome (hg18) using the ELAND alignment software within the Illumina Analysis Pipeline. Unique reads mapped to a single best-matching location with no more than two mismatches were kept and used to generate genome-wide distribution of ETV1 binding and for peak identification. Redundant reads were considered once. The software MACS 32 was applied to the ChIP-Seq data with sequencing data from input DNA as control for identifying genomic regions enriched with ETV1 ChIP signals (that is, peaks). For each peak, we subsequently calculated the number of reads (extending 200 nucleotides in the 39-direction) covering each nucleotide position and then defined the maximal count as the peak height. Using an FDR less than 1% (as defined by MACS) and a height of at least 15 reads, we defined 14,741 peaks. These peaks were classified as promoter peaks (within 62 kilobases (kb) of transcription start sites), enhancer peaks (from 250 kb of transcription start sites to 15 kb of transcription end sites, but excluding promoter regions) or otherwise intergenic peaks based on their genomic distances to known Refseq gene annotation. To associate an ETV1 peak with a specific gene, we used the following protocol. A promoter peak was assigned to all genes if it was in the promoter regions of multiple genes. An enhancer peak within a gene body was assigned to the host gene, but otherwise was assigned to the nearest gene. Nucleotide sequences of all ETV1 peaks were retrieved from the reference human genome and subjected to motif analysis by the program MEME 33 .
To correlate gene expression with ETV1-binding sites, we first limited the analysis to the genes with peaks to those that were also represented on the mRNA microarray (Illumina HumanHT-12). Overlapping analysis of genes whose expression was perturbed by ETV1 knockdown and those with ETV1 binding peaks was performed using Microsoft Excel macros, and significance was calculated using Fisher's exact test.
